MyVal-1 Study is a Prospective, Multicentre, single-arm, open label study of Myval-THV for the treatment of severe symptomatic native aortic valve stenosis. MyVal-1 Study has successfully completed the primary endpoint demonstrating high safety  and efficacy at 30-days, 6-months, and 1 year.

  • The unique crimping geometry of Myval ensures precise orthotopic device placement without any deep throating into the LVOT. 

  • This precise annular placement ensures that there is no conduction system disturbances thus eliminating need for a new pacemaker as seen with previous technologies.

  • The post-procedure mean aortic gradient, peak aortic gradient, and peak aortic velocity remained consistently low till the time of follow-up. 

  • There was a significant improvement in NYHA Class among patients after the procedure. Also, no post-procedure re-intervention was required during the follow-up upto 6 months.

Myval is a registered trademark of Meril Lifesciences Private Limited.
This product is intended for use by or under the direction of a trained healthcare practitioner only. Only qualified medical experts can give you information regarding your individual treatment. Prior to use, refer the instructions for use/IFU. Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Data, Photos and videos on file at Meril Lifesciences Pvt. Ltd.